Natalie Finn, Author at BioTuesdays

Executive Moves

Hepion expands SAB with appointments of four liver disease KOLs

Hepion Pharmaceuticals (NASDAQ:HEPA) added four new internationally recognized thought leaders to its scientific advisory board (SAB), effective immediately. These new members, who bring decades of liver disease...

March 30, 2023

Developments

Bolt posts positive Phase 1 data in HER2-expressing tumors

Bolt Biotherapeutics (NASDAQ:BOLT) reported positive topline data from its recently completed dose-escalation study of BDC-1001 in HER2-expressing solid tumors that support advancing into two Phase 2 studies. Topline...

March 30, 2023

Developments

Cognition presents proteomic biomarker data in Alzheimer’s

Cognition Therapeutics (NASDAQ:CGTX) presented results of a meta-analysis from the first cohort of 24 participants in the Phase 2 SHINE trial and the complete dataset from the Phase 1b SPARC studies in adults with mild...

March 28, 2023

Developments

NeuroSense, Mass General to collaborate on PrimeC in ALS

NeuroSense Therapeutics (NASDAQ:NRSN) signed a collaboration agreement with Dr. Ghazaleh Sadri-Vakili, Ph.D., and Massachusetts General Hospital’s NeuroEpigenetics lab to explore the neurotherapeutic effects of...

March 27, 2023

Developments

EyePoint completes enrollment in Phase 2 wet AMD trial

EyePoint Pharmaceuticals (NASDAQ:EYPT) completed enrollment in the Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial evaluating EYP-1901 as a potential six-month maintenance...

March 27, 2023

Developments

Atossa, Quantum Leap in new study arm of I-SPY 2 clinical trial

Atossa Therapeutics (NASDAQ:ATOS) and Quantum Leap Healthcare Collaborative announced that Atossa’s proprietary selective estrogen receptor modulator, (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I...

March 22, 2023

Markets

RJ highlights takeaways from KOL presentations on Profound’s TULSA-PRO

In a new report, Raymond James analyst, Rahul Sarugaser, Ph.D., outlined his five main takeaways from presentations from four key opinion leaders – Yale, UCLA, Mayo Clinic and WellSpan Health – about their clinical...

March 15, 2023

Developments

Reneo reaches target enrollment in pivotal trial in primary mitochondrial myopathies

Reneo Pharmaceuticals (NASDAQ:RPHM) achieved its target enrollment of 200 patients in the pivotal STRIDE study of mavodelpar in primary mitochondrial myopathies (PMM). Topline data from the STRIDE study are expected in...

March 14, 2023

Markets

Echelon starts Valeo Pharma at speculative buy; PT $1 (Canadian)

Echelon Capital Markets initiated coverage of Valeo Pharma (TSX:VPH) with a “speculative buy” rating and price target of $1 (Canadian). The stock closed at 55 cents on March 8. Valeo commercializes de-risked, innovative...

March 9, 2023

Developments

BioStem to acquire majority of assets of Auxocell Laboratories

BioStem Technologies (OTCQB:BSEM) agreed to acquire the majority of the assets of Auxocell Laboratories, a leading solid tissue processing equipment manufacturer. The Auxocell solid tissue processing device, AC:Px, is a...

March 7, 2023

Author - Natalie Finn

Hepion expands SAB with appointments of four liver disease KOLs

Bolt posts positive Phase 1 data in HER2-expressing tumors

Cognition presents proteomic biomarker data in Alzheimer’s

NeuroSense, Mass General to collaborate on PrimeC in ALS

EyePoint completes enrollment in Phase 2 wet AMD trial

Atossa, Quantum Leap in new study arm of I-SPY 2 clinical trial

RJ highlights takeaways from KOL presentations on Profound’s TULSA-PRO

Reneo reaches target enrollment in pivotal trial in primary mitochondrial myopathies

Echelon starts Valeo Pharma at speculative buy; PT $1 (Canadian)

BioStem to acquire majority of assets of Auxocell Laboratories

Subscribe